Amity Centre for Artificial Intelligence, Amity University, Noida, Uttar Pradesh, India; Centre for Advanced Studies, Dr. A.P.J. Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India.
Department of Biotechnology, Noida Institute of Engineering & Technology, Greater Noida, Uttar Pradesh, India.
Comput Methods Programs Biomed. 2024 Oct;255:108349. doi: 10.1016/j.cmpb.2024.108349. Epub 2024 Jul 22.
Breast cancer remains a leading cause of female mortality worldwide, exacerbated by limited awareness, inadequate screening resources, and treatment options. Accurate and early diagnosis is crucial for improving survival rates and effective treatment.
This study aims to develop an innovative artificial intelligence (AI) based model for predicting breast cancer and its various histopathological grades by integrating multiple biomarkers and subject age, thereby enhancing diagnostic accuracy and prognostication.
A novel ensemble-based machine learning (ML) framework has been introduced that integrates three distinct biomarkers-beta-human chorionic gonadotropin (β-hCG), Programmed Cell Death Ligand 1 (PD-L1), and alpha-fetoprotein (AFP)-alongside subject age. Hyperparameter optimization was performed using the Particle Swarm Optimization (PSO) algorithm, and minority oversampling techniques were employed to mitigate overfitting. The model's performance was validated through rigorous five-fold cross-validation.
The proposed model demonstrated superior performance, achieving a 97.93% accuracy and a 98.06% F1-score on meticulously labeled test data across diverse age groups. Comparative analysis showed that the model outperforms state-of-the-art approaches, highlighting its robustness and generalizability.
By providing a comprehensive analysis of multiple biomarkers and effectively predicting tumor grades, this study offers a significant advancement in breast cancer screening, particularly in regions with limited medical resources. The proposed framework has the potential to reduce breast cancer mortality rates and improve early intervention and personalized treatment strategies.
乳腺癌仍然是全球女性死亡的主要原因,其原因包括意识有限、筛查资源不足和治疗选择有限。准确和早期的诊断对于提高生存率和有效治疗至关重要。
本研究旨在通过整合多种生物标志物和受试者年龄,开发一种创新的人工智能(AI)基于模型,预测乳腺癌及其各种组织病理学分级,从而提高诊断准确性和预后预测能力。
引入了一种新的基于集成的机器学习(ML)框架,该框架整合了三种不同的生物标志物-人绒毛膜促性腺激素-β(β-hCG)、程序性细胞死亡配体 1(PD-L1)和甲胎蛋白(AFP)以及受试者年龄。使用粒子群优化(PSO)算法进行超参数优化,并采用少数过采样技术来减轻过拟合。通过严格的五折交叉验证来验证模型的性能。
该模型在精心标记的测试数据上表现出色,在不同年龄组中达到了 97.93%的准确率和 98.06%的 F1 分数。对比分析表明,该模型优于最先进的方法,突出了其稳健性和通用性。
通过对多种生物标志物进行全面分析,并有效预测肿瘤分级,本研究为乳腺癌筛查提供了重要进展,特别是在医疗资源有限的地区。该框架有潜力降低乳腺癌死亡率,并改善早期干预和个性化治疗策略。